Anika Therapeutics (ANIK) EBIAT (2016 - 2025)
Historic EBIAT for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$3.2 million.
- Anika Therapeutics' EBIAT rose 8938.77% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year increase of 6543.07%. This contributed to the annual value of -$56.4 million for FY2024, which is 3179.26% up from last year.
- Anika Therapeutics' EBIAT amounted to -$3.2 million in Q3 2025, which was up 8938.77% from -$4.6 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' EBIAT ranged from a high of $6.5 million in Q2 2021 and a low of -$63.0 million during Q4 2023
- For the 5-year period, Anika Therapeutics' EBIAT averaged around -$8.7 million, with its median value being -$4.5 million (2024).
- Its EBIAT has fluctuated over the past 5 years, first soared by 18473.02% in 2021, then tumbled by 118361.86% in 2023.
- Anika Therapeutics' EBIAT (Quarter) stood at -$5.8 million in 2021, then rose by 15.28% to -$4.9 million in 2022, then plummeted by 1183.62% to -$63.0 million in 2023, then skyrocketed by 65.29% to -$21.9 million in 2024, then soared by 85.48% to -$3.2 million in 2025.
- Its EBIAT was -$3.2 million in Q3 2025, compared to -$4.6 million in Q2 2025 and -$4.9 million in Q1 2025.